Efficacy and Tolerability of an Investigational Nitric Oxide-releasing Topical Gel in Patients With Molluscum Contagiosum: A Randomized Clinical Trial.
Although a variety of ablative, topical, and systemic therapies are used for molluscum contagiosum (MC), none have been well-studied or FDA-approved. To compare the efficacy and tolerability of topical SB206 (berdazimer sodium gel coadministered with hydrogel) with vehicle. A 12-week, phase 2, multicenter, randomized, double-blind, vehicle-controlled clinical trial of topical SB206. 256 patients (mean age, ∼7 years) were randomized. Of patients who completed 12 weeks of treatment (n=217), all MC lesions cleared in 20.0% of vehicle patients compared with 13.2%, 41.0%, and 35.1% of patients treated with twice daily SB206 4%, 8%, or 12%, respectively, and 41.9% of patients treated with once daily SB206 12%. Application-site erythema occurred in 10.6% of SB206 patients. Application-site reactions were the most common AEs leading to treatment discontinuation, affecting 2 patients (∼4%) in each of the SB206 4%, 8%, and 12% BID groups and 0 patients in the vehicle or SB206 12% QD groups. A larger study is needed to confirm SB206 12% QD efficacy and provide additional safety assessments. Of the doses studied, SB206 12% applied once daily provided the best balance between MC lesion clearance and tolerability for evaluation in a larger study.